http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190028540-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_872dd7cd609eb2a937dcfd303d521798 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate | 2017-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13537793f98a8fd042bd97b8d9b7ab81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e89c80d0d491556ef5dccf26183d8d93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_152f2ddc6d3635342c861217b70f8735 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5684cd2c0e00d601db2a8f3dfd7982d6 |
| publicationDate | 2019-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20190028540-A |
| titleOfInvention | Isoquinoline derivatives as PERK inhibitors |
| abstract | The present invention relates to substituted isoquinoline derivatives and uses thereof. In particular, the present invention relates to the use of a compound according to formula (I) and a compound of formula (I) in the treatment of a disease state: Wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and X are as defined herein. The compounds of the present invention are inhibitors of PERK and are useful in the treatment of diseases associated with cancer, pre-cancerous syndrome and activated unfolded protein response pathways such as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, Myocardial infarction, diabetes mellitus, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob disease, fatal familial insomnia, Gerstmann-Strauss-Schocker syndrome and associated prion diseases, amyotrophic lateral sclerosis, , Chronic traumatic encephalopathy (CTE), neuropathic pain, chronic pain and acute respiratory disease, pulmonary fibrosis, chronic and acute renal disease, kidney fibrosis, chronic traumatic encephalopathy In the treatment of dementia, dementia, frontal temporal dementia, tauopathy, Pick disease, niman-pick disease, amyloidosis, cognitive disorders, atherosclerosis, ocular disease, arrhythmia, May be useful in organ transplantation and in the transport of organs for transplantation. Accordingly, the present invention also relates to a pharmaceutical composition comprising a compound of the present invention. The present invention also relates to a method of inhibiting PERK activity and the treatment of disorders associated therewith using a pharmaceutical composition comprising a compound of the invention or a compound of the invention. |
| priorityDate | 2016-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1114.